Welcome to the MDS 2021 Interactive Programme
The congress will officially run on Eastern Daylight Time Zone EDT (Toronto time zone, UTC-4)
To convert the meeting times to your local time Click Here
Please note that all sessions will run at their scheduled time and be followed by a LIVE Q&A at the end
The viewing of sessions cannot be accessed from this congress calendar. All sessions are accessible via the Virtual Platform
Session Description:
This BMS-sponsored symposium will explore the current and future management of lower-risk MDS (LR-MDS) in clinical practice from the perspectives of leading experts, and will be chaired by Dr. Brian Leber. After an overview of current treatment goals and guidelines in LR-MDS, Prof. Sophie Park will discuss the benefits and limitations of erythropoiesis-stimulating agents (ESAs), including criteria for defining unsatisfactory treatment response and ESA failure. Next, Dr. Bart Scott will discuss when to consider switching patients from ESAs to alternative treatments, with an overview of key data from the latest clinical trials in LR-MDS. Before closing the symposium, the experts will host a live interactive Q&A session.